# Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

Study · id `cardio:ct-nct05209412` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05209412](<https://clinicaltrials.gov/study/NCT05209412>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05209412

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 370 participants.

## Technical summary

Registry record NCT05209412. Randomized; no masking; primary purpose treatment. Start 2022-02-01 (actual); primary completion 2024-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 370 participants (enrolled count; ClinicalTrials.gov record NCT05209412, source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)
- Started: 2022-02-01 (actual) (ClinicalTrials.gov record NCT05209412, source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)
- Primary completion: 2024-02-01 (anticipated) (ClinicalTrials.gov record NCT05209412, source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)
- Completion: 2025-02-01 (anticipated) (ClinicalTrials.gov record NCT05209412, source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05209412, source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05209412-2024-01-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
- Acronym: CAGE-FREEIII
- Condition: De Novo Stenosis
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Intervention (Device): Lepu Paclitaxel coated balloon
- Intervention (Device): Resolute Integrity Zotarolimus eluting stents
- Intervention (Drug): Aspirin
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Clopidogrel
- Lead sponsor: Xijing Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Xijing Hospital (`cardio:org-xijing-hospital`)

## Provenance

Content hash: fcdc328ef75a9ffbfb2dd20ae73946c30c400a54016036d3f50b6ec53f5e4e78
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
